

The Association of Haptoglobin Genotype with the Development of Liver Disease and a Strategy for Personalized Treatment of NASH

Nicole Shammass, Tiebing Liang, PhD
Indiana University School of Medicine, Department of
Gastroenterology/Hepatology

Background Haptoglobin is a binding protein that scavenges free hemoglobin and is highly expressed in the liver. The human haptoglobin gene (*HP*) is polymorphic, consisting of two alleles, *HP1* and *HP2*. Recent studies have found that haptoglobin variants are strongly associated with cholesterol levels, as haptoglobin is capable of binding apolipoprotein E and regulating HDL function³⁻⁴. Together, these functions allow haptoglobin to play a significant role in the transport of cholesterol from tissues to the liver. **Goal** Study the association of haptoglobin genotypes with the development of nonalcoholic steatohepatitis (NASH) using 2000 NASH CRN patient DNA samples. **Methods** Allelic differences were determined using TaqMan genotyping PCR and were analyzed on an ABI7300 real-time PCR machine. Following allele identification, the association between genotype and phenotype was determined, with focus on NASH scores and other relevant measurements. **Results** The distribution of haptoglobin genotype frequencies were 46% *HP1/HP2*, 39% *HP2/HP2*, and 15% *HP1/HP1*, with no gender differences. The results suggest that *HP2/HP2* is associated with specific liver disease states such as an NAFLD score of 6, fibrosis in zone 2 of the liver and periportal area, and a steatosis grade of 34-66%. The most abundant genotype observed was heterozygous for several ethnic groups, as expected. However, patients of Asian ancestry demonstrated homozygous *HP2* as the majority genotype. **Conclusion** *HP* genotype plays an important role in liver disease development. Genotyping distribution differences in ethnic groups may inform personalized treatment strategies, such as recommending Vitamin E for patients homozygous for *HP2*^{1 2}.

1. Zang, S.; Chen, J.; Song, Y.; Bai, L.; Chen, J.; Chi, X.; He, F.; Sheng, H.; Wang, J.; Xie, S.; Xie, W.; Yang, Y.; Zhang, J.; Zheng, M.; Zou, Z.; Wang, B.; Shi, J.; Chinese, N. C. R. N., Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. *Adv Ther* **2018**, 35 (2), 218-231.
2. Boettger, L. M.; Salem, R. M.; Handsaker, R. E.; Peloso, G. M.; Kathiresan, S.; Hirschhorn, J. N.; McCarroll, S. A., Recurring exon deletions in the *HP* (haptoglobin) gene contribute to lower blood cholesterol levels. *Nat Genet* **2016**, 48 (4), 359-66.
3. Spagnuolo, M. S.; Maresca, B.; La Marca, V.; Carrizzo, A.; Veronesi, C.; Cupidi, C.; Piccoli, T.; Maletta, R. G.; Bruni, A. C.; Abrescia, P.; Cigliano, L.,

Haptoglobin interacts with apolipoprotein E and beta-amyloid and influences their crosstalk. *ACS Chem Neurosci* **2014**, 5 (9), 837-47.

4. Costacou, T.; Levy, A. P.; Miller, R. G.; Snell-Bergeon, J.; Asleh, R.; Farbstein, D.; Fickley, C. E.; Pambianco, G.; de la Vega, R.; Evans, R. W.; Orchard, T. J., Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. *Acta Diabetol* **2016**, 53 (2), 243-50.